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HIF1/2-exerted control over glycolytic gene
expression is not functionally relevant for
glycolysis in human leukemic stem/
progenitor cells
Albertus T. J. Wierenga1,2, Alan Cunningham1†, Ayşegül Erdem1†, Nuria Vilaplana Lopera3†, Annet Z. Brouwers-Vos1,
Maurien Pruis1, André B. Mulder2, Ulrich L. Günther3, Joost H. A. Martens4, Edo Vellenga1 and
Jan Jacob Schuringa1*
Abstract
Background: Hypoxia-inducible factors (HIF)1 and 2 are transcription factors that regulate the homeostatic response to low
oxygen conditions. Since data related to the importance of HIF1 and 2 in hematopoietic stem and progenitors is conflicting,
we investigated the chromatin binding profiles of HIF1 and HIF2 and linked that to transcriptional networks and the cellular
metabolic state.
Methods: Genome-wide ChIPseq and ChIP-PCR experiments were performed to identify HIF1 and HIF2 binding sites in
human acute myeloid leukemia (AML) cells and healthy CD34+ hematopoietic stem/progenitor cells. Transcriptome studies
were performed to identify gene expression changes induced by hypoxia or by overexpression of oxygen-insensitive HIF1
and HIF2 mutants. Metabolism studies were performed by 1D-NMR, and glucose consumption and lactate production levels
were determined by spectrophotometric enzyme assays. CRISPR-CAS9-mediated HIF1, HIF2, and ARNT−/− lines were
generated to study the functional consequences upon loss of HIF signaling, in vitro and in vivo upon transplantation of
knockout lines in xenograft mice.
Results: Genome-wide ChIP-seq and transcriptome studies revealed that overlapping HIF1- and HIF2-controlled loci were
highly enriched for various processes including metabolism, particularly glucose metabolism, but also for chromatin
organization, cellular response to stress and G protein-coupled receptor signaling. ChIP-qPCR validation studies confirmed
that glycolysis-related genes but not genes related to the TCA cycle or glutaminolysis were controlled by both HIF1 and
HIF2 in leukemic cell lines and primary AMLs, while in healthy human CD34+ cells these loci were predominantly controlled
by HIF1 and not HIF2. However, and in contrast to our initial hypotheses, CRISPR/Cas9-mediated knockout of HIF signaling
did not affect growth, internal metabolite concentrations, glucose consumption or lactate production under hypoxia, not
even in vivo upon transplantation of knockout cells into xenograft mice.
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Conclusion: These data indicate that, while HIFs exert control over glycolysis but not OxPHOS gene expression in human
leukemic cells, this is not critically important for their metabolic state. In contrast, inhibition of BCR-ABL did impact on
glucose consumption and lactate production regardless of the presence of HIFs. These data indicate that oncogene-
mediated control over glycolysis can occur independently of hypoxic signaling modules.
Keywords: Hypoxia induced factors (HIFs), Human hematopoietic stem cells, Acute myeloid leukemia (AML), Glycolysis,
Hypoxia, BCR-ABL
Background
Hematopoietic stem cells (HSCs) and their leukemic stem
cell (LSC) counterparts reside within the bone marrow
microenvironment where they are surrounded by a wide
variety of other cell types that together constitute the stem
cell niche [1, 2]. Osteoblasts, osteoclasts, adipocytes, vas-
cular endothelial cells, and various other stromal compo-
nents provide the necessary factors that control stem cell
fate such as self-renewal, quiescence, dormancy, survival
and differentiation. Additionally, the bone marrow micro-
environment where HSCs reside is rather hypoxic [3, 4],
with the lowest O2 concentrations of 1.3% found in peri-
sinusoidal regions [5]. It is widely assumed that these con-
ditions in the niche further contribute to the quiescence
and metabolic state of HSCs [6–8], although the molecu-
lar mechanisms that are involved are only beginning to be
unraveled.
Hypoxia-inducible factors HIF1α and HIF2α act as oxy-
gen sensors that are degraded under normoxic conditions
but at lower oxygen levels HIF proteins are stabilized and
bind to their co-factor ARNT (HIF1β), before translocat-
ing to the nucleus to initiate gene transcription [9–11].
HIFs have been characterized as important factors con-
trolling cellular metabolism and self-renewal of HSCs [8,
12–15]. Hyperactivation of HIFs has been reported in
many cancers [16, 17], including in leukemias where they
might participate in the transformation process [18–21].
In chronic lymphocytic leukemia, metabolic plasticity in
response to hypoxia has been described, where the rate of
glucose consumption and lactate production was most
affected [22]. This metabolic adaptation was shown to be
HIF1-dependent and no longer possible when HIF1 was
inhibited using chetomin [22]. In contrast, it has also been
reported that HIF1 is dispensable for adult HSCs and that
they do not require intrinsic HIF1 to be able to respond to
injury [23] and the same was shown for HIF2 [24]. More
in line with that latter notion, HIF1 has also been identi-
fied as a tumor suppressor whereby HIF1 loss resulted in
enhanced leukemogenesis [25, 26]. These conflicting data
indicate that the exact role of HIF1 in the hematopoietic
system in health and disease remains far from clear, and
also the role of HIF2 is still under debate. Despite a high
homology between HIF1 and HIF2 suggesting a strong
overlap in functionalities, specific cellular roles for HIF1
and HIF2 have been described as well. In part, this might
also be dictated by their cell-type specific expression pro-
files, whereby HIF1 appears to be highest expressed in the
most immature HSC compartment [12] while HIF2 might
play a more prominent role in vascular endothelial cells
[27]. One of the most well documented roles of HIFs has
indeed been the upregulation of VEGF to induce angio-
genesis [9, 28, 29]. Previously, we identified HIF2 as a
downstream target of STAT5 and observed elevated glu-
cose uptake in STAT5 activated HSCs [30]. Several genes
associated with glucose metabolism were upregulated by
STAT5 in an HIF2-dependent manner, including SLC2A1
and GYS2 [30].
Under hypoxia, it has been shown that HIF1 can regulate
pyruvate dehydrogenase kinases (PDKs), thereby preventing
entry of pyruvate into the tricarboxylic acid cycle (TCA),
resulting in enhanced lactate production in quiescent HSCs
[31]. Indeed, an increasing number of papers have indicated
that to maintain a quiescent stem cell state, HSCs wire their
metabolic state towards glycolysis. HSCs self-renewal is better
maintained when mitochondrial activity is maintained low
[32] which might in part rely on mitochondrial clearance via
mitophagy [33]. In line with this, the reduction of reactive
oxygen species (ROS) by antioxidants maintains stemness in
serial transplantation experiments [34] and also in leukemia it
was proposed that the most immature LSCs with engraftment
potential reside within the ROSlow fraction [35]. Upon lineage
commitment, the PTEN-like mitochondrial phosphatase
PTPMT1 primes the switch to mitochondrial oxidative phos-
phorylation to support the energy demands in differentiating
HSCs [36]. Together, these studies highlight that distinct
metabolic programs exist in quiescent versus actively cycling
normal HSCs [37–39], although it is currently not clear how
these programs are controlled at the molecular level.
Although the role of HIFs in HSCs has remained con-
troversial, they do present as clear potential candidates to
control the metabolic state of cells. By performing tran-
scriptome studies, we and others previously identified that
metabolism-associated genes can be activated by HIFs [9,
10, 40]. In leukemias, we have observed that various onco-
genes can impose hypoxic signaling on normal human
hematopoietic stem and progenitor cells even when grown
under normoxic conditions [41–43]. Here, we set out to
identify the direct HIF1 and HIF2 targets at the chromatin
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level in the human hematopoietic system by performing
genome-wide ChIP-seq analyses, coupled to transcriptome
and metabolome changes induced by HIFs or hypoxia.
We report that, while HIFs can exert control over glycoly-
sis but not OxPHOS pathways in human leukemic cells,
this is not critically important for their metabolic state.
Methods
Cell culture and lentiviral transductions
Neonatal cord blood (CB) was obtained from healthy
full-term pregnancies from the Obstetrics departments
of the University Medical Center and Martini Hospital
in Groningen, The Netherlands, after informed consent.
The protocol was approved by the Medical Ethical Com-
mittee of the UMCG. Donors are informed about proce-
dures and studies performed with CB by an information
sheet that is read and signed by the donor, in line with
regulations of the Medical Ethical Committee of the
UMCG. CB CD34+ cells were isolated by density gradi-
ent separation, followed by the use of a hematopoietic
progenitor magnetic associated cell sorting kit from Milte-
nyi Biotech according to the manufacturer’s instructions.
Lentiviral transductions were essentially performed as de-
scribed elsewhere [2–4].
Generation of CRISPR/Cas9 lines
HIF1α, HIF2α, and ARNT were functionally knocked
out by CRISPR/Cas9, as described in detail in the Add-
itional file 7: Supplementary methods.
ChIP-seq and ChIP-q-PCR
K562 cells were transduced with the lentiviral GFP-fusion
vectors encoding HIF1α and HIF2α. 1 × 106 EGFP positive
cells were sorted and subsequently fixed in 1% formalde-
hyde for 10 min, quenched with 0.1 M glycine and proc-
essed for ChIP. Detailed methods including the used
primers for ChIP-qPCR are described in the Additional
files. ChIP reactions were performed using the following
antibodies: anti-GFP (ab290, Abcam), anti-HIF1α (NB100-
134, R&D systems), HIF2α (NB100-122, R&D systems),
and ARNT (NB100-110, R&D systems). ChIP-seq data is
deposited at GEO under GSE123461. Additional Materials
and Methods can be found in the Additional files.
Results
HIF1 and HIF2 control glycolysis-related genes in human
leukemic cells
Chromatin immunoprecipitation (ChIP)-sequencing was
performed in order to identify HIF1 and HIF2-bound loci
in human leukemic cells. The oxygen insensitive HIF mu-
tants HIF1α(P402A,P564A)-EGFP and HIF2α(P405A,
P531A)-EGFP (described previously in [40, 44]) were
expressed as EGFP-fusion proteins in K562 cells. The HIF
proline residues become hydroxylated under normoxic
conditions which leads to their degradation, which is pre-
vented by mutating these residues into alanines [45]. Anti-
EGFP ChIPs were performed as outlined previously [30,
46], followed by deep sequencing. 50–60% of all identified
peaks were located close to transcription start sites (TSSs,
− 5kb to + 1 kb, Additional file 1: Figure S1a, Additional
file 8: Table S1). Given the relatively large number of HIF
binding sites distant from TSSs, we also analyzed whether
HIFs would control lncRNAs or bind to super enhancers
(SEs). Indeed, 13 to 15% of HIF1 and HIF2 peaks, respect-
ively, were found to be located close to start sites of
lncRNAs (Additional file 1: Figure S1b), while no signifi-
cant enrichment of HIF binding was detected close to SEs
(data not shown).
Of the 3871 HIF1 peaks close to TSSs, 581 overlapped
with HIF2 peaks (Fig. 1a–c). This overlapping set of
HIF-bound loci was strongly enriched (FDR < 0.01) for
various Reactome Pathway terms associated with metab-
olism, including “glycolysis,” “glucose metabolism,” and
“gluconeogenesis,” but also for terms associated with
chromatin organization and GPCR signaling (Fig. 1d,
Additional file 1: Figure S1c). Loci more strongly bound
by HIF1 were enriched for rather distinct processes such
as cell cycle, DNA repair, vesicle-mediated transport and
mRNA splicing (Fig. 1e), while no significant enrichment
was observed for loci that were more strongly bound by
HIF2 (data not shown).
A motif search on HIF1- and HIF2-bound promoters
to identify other transcription factors that might act to-
gether with HIFs revealed that both HIF1 and HIF2
peaks were strongly enriched for NRF1, SP1, ELK1, and
HIF motifs (within − 5 kb to + 1 kb around the TSS)
(Additional file 8: Table S1). While no motifs were found
to be specifically enriched around HIF2 peaks, a series of
motifs were identified that were specifically present
around HIF1 bound promoters, including binding sites
for ATF3, CREB1, JUN, MAX, MYB, MYC, and ETS1
(Additional file 8: Table S1).
Chromatin binding was compared to gene expression
changes (> 2-fold) induced by expression of the oxygen-
insensitive HIF1α(P402A,P564A)-EGFP and
HIF2α(P405A,P531A)-EGFP mutants in K562 cells, and
also to transcriptome changes induced upon culturing of
K562 cells under hypoxia (Fig. 1f). For the upregulated
genes, a number of specific clusters could be identified
that were predominantly upregulated by HIF1, HIF2, hyp-
oxia, or all. Interestingly, this also allowed the identifica-
tion of sets of genes controlled by hypoxia, independent of
HIF transcription factors (Fig. 1f, cluster 1). Thirty-nine of
the HIF1-upregulated genes (442/1139) were also directly
bound by HIF1, while for the downregulated genes this
was only 23% (359/1534) (Fig. 1g). For HIF2, the overlap
between differentially expressed genes and those that were
directly bound by HIF2 was smaller but for both HIF1 and
Wierenga et al. Cancer & Metabolism            (2019) 7:11 Page 3 of 17
HIF2 the overlapping bound and upregulated loci were
strongly enriched for glycolysis-associated genes, while for
HIF1 the overlapping downregulated loci were strongly
enriched for reactome pathway terms “cell cycle,” “DNA
repair,” and “mRNA splicing” (Fig. 1g, Additional file 9:
Table S2). Furthermore, we ranked and identified the top
200 strongest bound loci by HIF1 and HIF2 and per-
formed gene set enrichment analyses (GSEA) using
differentially expressed gene sets induced by HIF1, HIF2
or hypoxia. These analyses again confirmed that the stron-
gest bound genes are also the most strongly upregulated
by HIF1 or HIF2, and also that these HIF-bound loci are
strongly upregulated under hypoxic conditions (Fig. 1h).
To determine similarities and differences between HIF-
bound loci across different cell types, we compared our ChIP-
seq data from human leukemic cells with published data in
Fig. 1 Identification of HIF1 and HIF2 chromatin binding sites in human leukemic cells. a. HIF1(P402A,P564A)-EGFP and HIF2(P405A,P531A)-EGFP
fusions were expressed in K562 cells and anti-EGFP ChIPs were performed. VENN diagram depicts specific and overlapping peaks. H3K4me3, H3K27ac,
and H3K27me3 K562 tracks were retrieved from Encode. b. Heatmaps of overlapping ChIP-seq peaks shown in a. c Left: representative examples of
screenshots of loci bound by both HIF1 and HIF2, top right: representative screenshot of an HIF1-specific locus and bottom right: representative
screenshot of an HIF2-specific locus. y-axis scales are set to 100 for HIF1 and HIF2, and to 50 for the other tracks. d–e GO analyses of gene loci bound
by both HIF1/2 (f) or HIF1 only (g). f Supervised clustering of genes upregulated (> 2-fold) under hypoxia or upon overexpression of HIF mutants in
K562 cells. 1, genes predominantly upregulated by hypoxia; 2, genes predominantly upregulated by HIF1; 3, genes predominantly upregulated by
HIF1/HIF2; 4, genes predominantly upregulated by HIF2; 5, genes upregulated by HIH1/HIF2 and hypoxia. g Overlap in HIF-bound loci determined by
ChIP seq and HIF-induced gene expression changes. Reactome Pathway GO analyses was performed on overlapping genes as indicated. h GSEA
analyses showing good correlations between HIF binding and HIF-induced gene expression, as well as between HIF binding and hypoxia-induced
gene expression
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breast cancer MCF7 cell lines [47, 48]. These analyses again
confirmed that glucose metabolism and in particular glycoly-
sis are processes that are controlled by both HIF1 and HIF2
independent of cell type (Additional file 1: Figure S1d, 1e).
Since HIF1 and HIF2 induced overlapping but also spe-
cific genes, we analyzed the co-occurrence of transcription
factor (TF) binding motifs at HIF1 and HIF2-bound loci.
Among the top scoring motifs, we observed NRF1 and
ELK1 (Additional file 2: Figure S2a-c). Since for both of
these, K562 ChIPseq tracks were available in ENCODE,
we analyzed whether HIF1/2-bound loci would also be
bound by NFR1 and ELK2. Indeed we observed that close
to the TSS, binding of all factors was frequently observed,
in particular in the case of glycolysis-related genes (Add-
itional file 2: Figure S2d). While no HIF2-unique co-
occurring TF motifs were found, we did find HIF1-unique
co-occurring TF-binding motifs. Possibly, these differ-
ences also underlie HIF-specific target gene regulation but
additional studies are required to obtain further insights
into these phenomena.
ChIP-seq data was then confirmed at the endogenous
level in leukemic cell lines and primary patient samples,
as well as in healthy human CD34+ stem/progenitor
cells. As shown in Fig. 2a, both endogenous HIF1 and
HIF2 binding to glycolysis-related genes was observed in
K562 cells grown under hypoxia. Also, endogenous HIF
binding to glycolysis-related genes could be induced
when cells were stimulated with DMOG under nor-
moxic conditions to stabilize HIF transcription factors,
albeit to different levels as compared to cells that were
grown under hypoxia. In healthy CB CD34+ cells, a
strong HIF1 binding to glycolysis-related loci was also
observed, where HIF2 binding was not detected, suggest-
ing that in normal cells it is particularly HIF1 that exerts
control over glycolysis genes (Fig. 2b).
In primary patient AML CD34+ cells, we observed that
both HIF1 and HIF2 associated with glycolysis-related
loci, although patient-specific differences were also noted,
whereby HIF1 binding was more dominant than HIF2 in
some cases (Fig. 2c, d). We compared HIF binding in pri-
mary AML CD34+ cells derived from the hypoxic bone
marrow environment and compared that to more nor-
moxic peripheral blood-derived AML CD34+ but in two
tested cases comparable results were obtained (Fig. 2e).
We also wished to compare ChIP efficiencies using en-
dogenous and tagged HIF approaches. We overexpressed
HIF1 and HIF2 EGFP fusion proteins (in K562 cells) with
an empty EGFP expressing vector as control. The cells
were sorted for EGFP expression and incubated under
normoxia or hypoxia (24 h) as indicated (Additional file 3:
Figure S3a). ChIP-QPCR was performed using antibodies
against EGFP (recognizing HIF:EGFP fusions), and HIF1
and HIF2 (recognizing HIF:EGFP fusions as well as en-
dogenous HIF). As shown in Additional file 3: Figure S3a,
the amount of HIF:EGFP fusions was approximately equal
on a common HIF locus (ALDOA) when precipitated by
αEGFP antibodies (green bars). Precipitation with anti-
bodies against HIF1 and HIF2 resulted in comparable sig-
nals for the different antibodies (although with a slightly
lower signal for HIF2), showing that the HIF antibodies
have rather comparable affinities. However, the control
group incubated under hypoxia (without HIF:EGFP over
expression), shows an approximately tenfold higher HIF1
signal compared to HIF2, indicating that under these con-
ditions the amount of chromatin-bound HIF1 is tenfold
higher than the amount of HIF2. On the basis of these ob-
servations we conclude that our overexpression models
result in HIF chromatin binding and transcriptional activ-
ities that are relatively comparable to the hypoxia-induced
endogenous levels, whereby we also make note of the fact
that our HIF2 models probably overestimate the true en-
dogenous role under hypoxia in our cellular systems. No
HIF was present on a non-binding locus (GATA5,
Additional file 3: Figure S3b).
Glycolysis but not TCA cycle or glutaminolysis-related
genes are controlled by hypoxia and HIFs
Since ChIP-seq and transcriptome studies indicated that
HIFs in particular control glycolysis but not other
metabolism-associated processes, we wished to extend
our analysis to other cellular systems and generate a
comprehensive detailed map of direct HIF binding and
transcriptional control over all enzymes mediating gly-
colysis, TCA cycle and glutaminolysis (Fig. 3a). First, we
performed genome-wide transcriptome studies across a
panel of human leukemic cells lines as well as in normal
CB CD34+ stem/progenitor cells upon culturing under
hypoxia. Only glycolysis-related genes were upregulated
under hypoxia, while for TCA cycle or glutaminolysis-
related genes no difference or in some cell lines even a
general decrease in expression was observed (Fig. 3b).
Interestingly, cell type-specific differences were also
noted in the hypoxia-induced changes in glycolysis-
related genes, for instance in the case of glucose
importers (SLC2A1, SLC2A3), PFKL and the lactate ex-
porter SLC16A3, suggesting that depending on the
genetic background cells respond differently. Similar to
culturing under hypoxia, expression of oxygen-
insensitive HIF1α(P402A,P564A)-EGFP or
HIF2α(P405A,P531A)-EGFP consistently induced upreg-
ulation of glycolysis-related genes but not TCA cycle or
glutaminolysis-related genes, both in normal CB CD34+
cells as well as across a panel of leukemic cell lines (Fig.
3b, 3c). We also performed quantitative proteome ana-
lyses in K562 cells grown under hypoxia for 24 h and
these studies further confirmed upregulation of
glycolysis-related genes at the protein level (Fig. 3b).
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We then analyzed the level of direct HIF binding to
glycolysis, TCA cycle, and glutaminolysis-related genes
and observed that in fact almost all promoters of
glycolysis-related genes were bound by HIF1, while for
TCA cycle-related genes this was only 23% (Fig. 3d, e).
Similarly, we observed that 77% of the promoters of
glycolysis-related genes were bound by HIF2, while for
TCA cycle-related genes this was only 8% (Fig. 3d, e).
The strongest HIF1 binding was observed to ENO1,
followed by GPI1, PDK1, SLC16A3, ALDOA, SLC2A3,
Fig. 2 Validation of identified HIF1 and HIF2-bound loci in endogenous ChIP-PCRs. a HIF1 and HIF2 occupied loci identified by ChIPseq were
validated in K562 using antibodies against endogenous HIF1 and HIF2. b HIF1 is more efficiently stabilized under hypoxia compared to HIF2 in CB
CD34+ cells. Numbers below x-axis indicate patient sample numbers. c–d endogenous HIF1 and HIF2 ChIP PCRs on representative loci in primary
AML CD34+ cells. e Endogenous HIF1 and HIF2 ChIP PCRs on representative loci in primary AML CD34+ cells derived from BM or PB. Numbers
above graphs indicate patient sample numbers, whereby 2009-125 is derived from BM and 2009-126 is derived from PB from the same patient;
2007-043 is derived from BM and 2007-047 is derived from PB from the same patient
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PGK1 and PFKP, and for HIF2 similar binding profiles
were seen except for ENO1 where binding was signifi-
cantly weaker compared to HIF1 (Fig. 3d). For compari-
son, we also plotted peak heights for HIF1 and HIF2
binding to glycolysis and TCA related genes in MCF7
cells published by Schödel et al. [47].
Since cancer cells have been suggested to be intrinsically
glycolytic, and also since we previously noted that human
CD34+ cells expressing various oncogenes have been
described to express hypoxic gene signatures even when
cultured under normoxic conditions [41], we questioned
whether at baseline under normoxic conditions the ex-
pression of glycolysis, TCA cycle or glutaminolysis-related
genes would be different between normal CD34+ stem/
progenitor cells and leukemic cells. We noted a consistent
upregulation of glucose importers SLC2A1 and SLC2A3
in leukemic cells, but also various other glycolysis-related
genes were upregulated in leukemia although variation
Fig. 3 Glycolysis but not TCA activity is controlled by hypoxia and HIFs.a Schematic representation of glycolysis, TCA, and glutaminolysis
pathways. b Hypoxia induces glycolysis but not TCA genes in normal CB CD34+ and leukemic K562, HL60, and OCI-AML3 cells. As comparison,
transcriptome changes induced by overexpression of oxygen-insensitive HIF mutants in K562 cells grown under normoxia is shown in the last
two columns. The last column shows the quantitative proteome data of K562 cells grown under hypoxia (24 h) or normoxia and the fold
change in protein expression is shown. c Transcriptome changes in CB CD34+ cells and various leukemic cell lines upon overexpression of
HIF1(P402A, P564A)-EGFP and HIF2(P405A, P531A). Transcriptome data is shown as fold change over controls. d ChIPseq data showing binding
to glycolysis but not TCA loci. Peak heights are shown. For comparison, we also plotted peaks heights for HIF1 and HIF2 binding to glycolysis
and TCA-related genes in MCF7 cells published by Schödel et al [47]. e Pie charts showing the relative binding of HIF1 and HIF2 to glycolysis-
related loci and TCA-related loci. When at least one isoform of each enzyme was bound by HIFs at each consecutive step in these pathways
then the total was 100%, as was seen for HIF1 bound to glycolysis-related loci
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between different cell lines was noted as well (Fig. 4a, b).
In fact, also various TCA cycle-related genes were higher
expressed in leukemias compared to normal CD34+ cells,
and the same was seen for some glutaminolysis-related
genes. In particular, K562 cells showed an upregulation of
the glutamine importer SLC1A5 and the glutamine-to-
glutamate converting enzyme GLUL (Fig. 4a), in line with
previous data showing that overexpression of BCR-ABL in
human CD34+ cells as well as primary CML patient sam-
ples display enhanced glutaminolysis [41].
We further investigated expression of glycolysis-
related genes in primary AML patient samples (taken
from the Bloodspot database [49]) compared to normal
stem/progenitor cells. As shown in Fig. 4c, a number of
glycolysis genes were consistently upregulated in pri-
mary AML cells representing different risk categories,
and in particular an upregulation of SLC2A3, PKM,
PDK1, PDK2 and SLC16A3 was noted. TCA-related
genes were typically downregulated in AML compared
to normal stem/progenitors, while GLS was downregu-
lated and GLUL upregulated (Fig. 4c). A modest but sig-
nificant upregulation of HIF1, HIF2, and ARNT was
observed as well in AML (Fig. 4d).
Generation of CRISPR/Cas9-mediated specific HIF1, HIF2,
and ARNT knockout lines
In order to functionally study the role of HIF transcription
factors in controlling glycolysis under hypoxia, we generated
specific HIF1, HIF2 and ARNT knockout K562 lines using a
CRISPR/Cas9 approach. Several single cell-derived knockout
lines were generated and the introduction of loss-of-function
mutations was validated by Sanger sequencing (Supplemen-
tary Materials and Methods). Multiple validated single cell-
derived clones (typically 4) were then again combined in
order to rule out individual clone-specific phenotypes, and
all data was generated using these pooled lines. Western blot
using antibodies against HIF1α, HIF2α and ARNT was per-
formed to confirm knockout of the respective genes (Fig. 5a).
In order to functionally validate our CRIPR/Cas9 lines, we
performed ChIP-PCRs using antibodies against endogenous
HIF1, HIF2, or ARNT both under normoxia as well as under
hypoxia. Several loci were investigated and representative
data for ALDOA and GPI are shown in Fig. 5b. A clear in-
duction of HIF1, HIF2, and ARNT binding was observed
under hypoxia in wild type (wt) K562 cells. Specific loss of
HIF1 binding was observed in HIF1−/− lines, specific loss of
HIF2 binding was observed in HIF2−/− lines, and no HIF1 or
HIF2 binding was observed in ARNT-/- lines, as expected
(Fig. 5b). In the absence of either HIF1 or HIF2, some ARNT
binding was still observed on the ALDOA locus, indicating
that expression of either one of these HIF factors is sufficient
to recruit ARNT to the chromatin.
Next, we questioned whether the expression of glycoly-
sis genes would be affected upon loss of HIF signaling. In
initial experiments, cells were grown under hypoxia for 24
h after which RNA was isolated for analyses. As shown in
Fig. 5c for 6 examples, knockout of ARNT strongly im-
paired the hypoxia-induced upregulation of these genes.
We also performed a quantitative proteome analyses on
either wt cells or ARNT−/− K562 cells grown under nor-
moxia or under hypoxia for 24 h. As depicted in Add-
itional file 4: Figure S4a, the hypoxia induced upregulation
of glycolysis-related proteins was largely HIF-dependent.
In order to determine whether glycolysis-related genes
could be re-expressed in our CRISPR knockout lines, we
re-introduced the oxygen-insensitive HIF1 and HIF2 mu-
tants in the HIF1−/− or HIF2−/− K562 cells, respectively.
Next, we isolated mRNA from cells grown under hypoxia
or normoxia for 24 h, performed Q-RT-PCRs, and show
that re-expression of HIFs results in elevated expression
of glycolysis-related genes (Additional file 4: Figure S4b).
Remarkably, loss of HIF1 had a much stronger impact
on the hypoxia-induced upregulation of glycolysis genes
as compared to HIF2 loss, suggesting that under these
early acute hypoxic stress conditions, HIF1 is more im-
portant to control expression of these genes. To investi-
gate this further, we also analyzed mRNA from cells that
had been grown under chronic hypoxia conditions for a
period of 10 days. Loss of ARNT still impaired the
hypoxia-induced upregulation of several glycolysis genes
as well as the HIF target BNIP3. For the glucose trans-
porters SLC2A1 and SLC2A3, a clear compensatory ef-
fect was noted whereby both HIF1 or HIF2 could drive
expression of these genes together with ARNT under
hypoxia (Fig. 5c), although other HIF-independent com-
pensatory mechanisms might play a role as well. In con-
trast, hypoxia-induced expression of PDK1 and PDK3
and also BNIP3, remained rather dependent of HIF1
specifically (Fig. 5d).
Loss of HIF signaling does not impact on proliferation or
the metabolic state of cells under hypoxia
In order to functionally study the cell biological conse-
quences for loss of HIF signaling under hypoxia, a num-
ber of studies were undertaken. First, cell proliferation
was investigated and a slight reduction in proliferation
rate was observed when cells were grown under chronic
hypoxia, but surprisingly the absence of HIF signaling
did not impact on the proliferation rate (Fig. 6a). When
cells were plated and grown under higher cell densities
(starting at 0.1 × 106 cells per ml), proliferation was
more strongly reduced under hypoxia conditions but
also under those conditions loss of HIF signaling did not
impact at all on the proliferation rate (data not shown).
In order to validate whether our cells adopted a glyco-
lytic metabolic state under hypoxia we determined
glucose consumption and lactate production levels by
spectrophotometric enzyme assays. As shown in Fig. 6b,
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c, both glucose consumption and lactate production
were increased upon culturing under hypoxia, as ex-
pected, but surprisingly knockout of HIF1, HIF2 or
ARNT did not impact on the glycolytic state of cells at
all. This occurred independent of whether cells were an-
alyzed under acute hypoxic stress conditions (24 h, Fig.
6b,c) or under chronic hypoxia conditions (day 10, Add-
itional file 5: Figure S5a). In order to determine whether
these observations would be specific for leukemic cells,
healthy CB-derived CD34+ cells were transduced with
shRNA lentivectors to downregulate ARNT (Additional
file 5: Figure S5b), after which cells were plated under
normoxia or hypoxia. Again, no impact on cell prolifera-
tion was noted (data not shown). And while hypoxia
nicely induced a shift towards a more glycolytic meta-
bolic state, the loss of HIF signaling did not impact on
the level of glucose consumption or lactate production
under acute or chronic hypoxic conditions (Additional
file 5: Figure S5b). This was despite an efficient knock-
down of ARNT and consequently a loss of HIF-
Fig. 4 Leukemic cells adopt hypoxia like glycolytic signaling under normoxic conditions and various glycolytic genes are upregulated across
multiple AML subtypes. a A number of glycolysis and TCA genes are upregulated in leukemia cell lines compared to normal CB CD34+ cells
under normoxic conditions. A heatmap of gene array data is shown whereby expression levels in CB CD34+ cells were set to 1. b Expression of
SLC2A1 and SLC2A3 under normoxic and hypoxic conditions in normal CB CD34+ cells and leukemia lines. c Expression of glycolysis, TCA, and
glutaminolysis genes in primary AML patient samples. Data were taken from the bloodspot database. d Expression of HIF1, HIF2, and ARNT in
primary AML patient samples
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mediated upregulation of glycolytic genes like ALDOC
and PDK1 upon hypoxic growth (Additional file 5: Fig-
ure S5c).
Since these findings were unexpected, we referred to al-
ternative methods to study the metabolic state of cells and
performed 1D-NMR studies in order to quantify several
intracellular and extracellular metabolites in K562 HIF1,
HIF2, and ARNT knockout cells grown under hypoxia or
normoxia. While several intracellular metabolites changed
upon culturing under hypoxia, including an increase in
lactate production, the loss of HIF1, HIF2, or ARNT did
not impact on most of these hypoxia-induced changes
(Fig. 6d, Additional file 6: Figure S6). Besides changes in
lactate production, several other intracellular metabolites
were affected by hypoxia, most notably significant reduc-
tions in the antioxidant glutathione, which is required to
detoxify reactive oxygen species. Also significant reduc-
tions in phosphocholine/choline were noted, suggesting
that phosphatidylcholine synthesis via the Kennedy path-
way is affected [50]. Various changes in intracellular
amino acids were noted as well, including increases in the
essential branched-chain amino acids leucine, isoleucine
and valine under hypoxia. However, none of these levels
were affected by loss of HIF1, HIF2, or ARNT. The only
consistent changes we noted were that the hypoxia-
induced increases in intracellular myo-inositol, formate,
and acetate were lost upon knockout of HIF signaling,
while the hypoxia-induced reduction in intracellular
Fig. 5 Generation of CRISPR/Cas9-mediated knockout K562 lines for HIF1, HIF2, and ARNT. a Single-cell-derived knockout lines were generated
and validated by sequencing after which 4 single cell-derived lines were pooled for further analyses. Cells were grown for 24 h under hypoxia
and extracts were western blotted for the presence of HIF1, HIF2, and ARNT. b K562 cells were treated as in a, and ChIP Q-PCR experiments were
performed. The knockout is shown below the x-axis, the antibodies used for ChIP-PCRs are shown in the colored boxes (HIF1 in top panels, HIF2
in middle panels, ARNT in lower panels), and the loci to which binding is investigated is shown at the top (ALDOA for left panels and GPI for
right panels). c Q-PCR was performed on knockout lines. Cells were grown under hypoxia for 24 h. d Experiment as in c but now cells were
grown under hypoxia for 10 days to evaluate gene expression changes under chronic hypoxia conditions
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creatinine was not as pronounced in the absence of HIFs
(Fig. 6d, Additional file 6: Figure S6).
We also performed time course 1D-NMR on the
medium in which cells were grown at several time points,
either under normoxia or hypoxia. Over the time course
of the experiments, cells consumed significant amounts of
glutamine, the branched amino acids leucine, isoleucine,
and valine, but only the consumption of glucose was
significantly enhanced by hypoxia (Fig. 6e). Reversely, a
significant increase in lactate production was observed
under hypoxia, but in line with our previous data, the ab-
sence of HIFs did not impact on the hypoxia-induced
glycolytic state (Fig. 6e).
In order to evaluate whether loss of HIF signaling would
impact on tumor development in vivo, we injected our
CRISPR-Cas9 knockout cells into immunodeficient NSG
Fig. 6 Loss of HIF signaling does not impair hypoxia-induced glycolysis. a Growth curves of K562 HIF1, HIF2, and ARNT knockout cells under
hypoxia and normoxia. b–c Glucose consumption (b) and lactate production (c) of K562 HIF1, HIF2, and ARNT knockout cells grown under
normoxic and hypoxic growth conditions for 24 h. *p < 0.05. d 1D 1H-NMR extract metabolite intensities from K562 and ARNT knockout cells
grown under hypoxia or normoxia for 24 h. e 1D 1H-NMR medium metabolite intensities from K562 wildtype (wt) and ARNT knockout cells
grown under hypoxia and normoxia with medium collection at 18, 21, and 24 h for analysis to calculate the rate of production/consumption of
indicated metabolites
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mice (n = 5 per group). As shown in Fig. 7a, no effects
were observed on the latency of tumor development upon
loss of either HIF1, HIF2, or ARNT. Some mice did not
develop tumors at all, in line with the notion that K562
cells do not engraft well in some transplanted animals.
We did note a slight trend towards a latency of leukemia
onset in HIF1−/− animals but this did not reach signifi-
cance and was also not noted in mice transplanted with
ARNT−/− cells, in which HIF signaling is completely ab-
sent. Furthermore, we quantified several intracellular me-
tabolites from extracted tumor cells by 1D-NMR studies
and these results also did not reveal differences in glycoly-
sis upon loss of HIF signaling in vivo (Fig. 7b).
Inhibition of BCR-ABL tyrosine kinase activity does impair
glycolysis independent of hypoxia and HIF signaling
Next, we questioned whether inhibition of signaling net-
works downstream of the oncogene BCR-ABL would
impact on glycolysis. We performed glucose consump-
tion and lactate production assays in K562 cells treated
with increasing doses of imatinib. In contrast to loss of
HIF signaling, inhibition of BCR-ABL kinase activity did
result in reduced glycolysis in a dose-dependent manner
(Fig. 8a and b). While culturing under hypoxia resulted
in enhanced glycolysis as expected, a comparable reduc-
tion in glucose consumption and lactate production
upon Imatinib treatment was observed under normoxic
and hypoxic conditions, and also loss of HIF signaling as
a consequence of ARNT knockout did not impact on
the glycolytic state (Fig. 8a, b). These data clearly indi-
cate that BCR-ABL mediated control over glycolysis oc-
curs independently of hypoxic signaling modules.
Discussion
In the current study, we aimed to obtain a deeper
insight into the roles of HIF transcription factors in
human hematopoietic stem and progenitor cells and
their leukemic counterparts. While we initially hy-
pothesized that various metabolic features would par-
ticularly be under the control of HIFs, we conclude
that even though the vast majority of the glycolysis-
related loci are directly regulated by HIFs under hyp-
oxia, this control is not strictly required to adopt a
glycolytic metabolic state under acute or chronic hyp-
oxic conditions.
Fig. 7 Loss of HIF signaling does not impair leukemia development in vivo. a K562 wt, HIF1, HIF2, and ARNT (n = 5) knockout cells were injected
into sublethally irradiated NSG mice (n = 5 per group) and leukemia development was monitored. No significant differences in overall survival
were observed. b Tumors (wt n = 2, HIF1 n = 2, HIF2 n = 4, gARNT n = 2) were harvested from leukemic mice and were subjected to 1D 1H-NMR
analyses in order to quantify intracellular metabolite levels
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We carefully mapped all genomic loci that are directly
bound by either HIF1 or HIF2 in human hematopoietic
leukemic cells and linked this to transcriptional changes
induced under hypoxia and this provided a comprehen-
sive view on their potential cell biological roles. As ex-
pected, we identified known targets like VEGFA and
VEGFB as loci that were directly bound and strongly up-
regulated by both HIF1 and HIF2 (Additional files 8 and
9: Tables S1 and S2) [9, 28, 29]. Less expected was the
observation that HIFs can also directly control various
chromatin modifying enzymes. This also included a
number of histone methyltransferases, deacetylases and
demethylases, in line with data published previously in
liver cells [51], leaving open the possibility that the epi-
genome might change under hypoxic conditions, in part
via HIF signaling, a notion that will be further investi-
gated. But among the most strongly bound and upregu-
lated HIF loci, we identified genes that were
predominantly associated with the glycolytic metabolic
program. This included for instance PFKFB4, which is a
bifunctional kinase/phosphatase that regulates the con-
centration of the glycolytic by-product fructose-2,6-
bisphosphate (F2,6BP) [52]. We did not find evidence
for HIF-exerted transcriptional regulation control over
the Krebs cycle enzymes, the pentose phosphate path-
way, gluconeogenesis, or the glutaminolysis pathway,
and in fact many of these genes were down regulated
under hypoxia or upon overexpression of HIF mutants,
both in our model systems as well as in primary AML
patient samples. In contrast, we did observe a direct
control of HIFs over virtually all metabolic steps of the
glycolytic pathway, in line with previously published data
in breast and liver cancer cell lines [47, 48, 51]. Multiple
homologues of enzymes exist at various levels of this
pathway that are considered to be able to mediate the
glycolytic flux, as is for instance the case for the glucose
transporters SLC2A1 and SLC2A3, and the enolases
ENO1 and ENO2 and all of these were strongly bound
and upregulated by HIFs. At the level of phosphofructo-
kinase, it was particularly PFKL and PFKP but not
PFKM that was under HIF control, in line with what we
observed in primary AML patient samples. Some specifi-
city in HIF signaling was also observed, and for instance at
the level of the hexokinases, we observed that HK1 and
HK2 were exclusively controlled by HIF1 and not HIF2.
These data suggested that HIFs would not merely in-
duce a glycolytic cellular state by controlling very spe-
cific rate-limiting steps of glycolysis but rather that it is
ensured that all components of the complete pathway
remain expressed at sufficient levels under hypoxic con-
ditions. We then further challenged this notion by func-
tional studies in which we knocked out HIF signaling
using a CRIPSR-Cas9 approach. In the complete absence
of HIF signaling, by knocking out HIF1, HIF2 or the
essential co-factor ARNT, we observed that the hypoxia-
induced upregulation of glycolysis-associated genes was
almost completely abrogated. Surprisingly, however, no
effects were seen on the hypoxia-induced increase in
glucose consumption or lactate production as deter-
mined by various assays at both the intracellular and
extracellular level, under acute and more chronic hyp-
oxia conditions, both in normal CD34+ cells as well as in
leukemic cells. These data clearly contradict earlier sug-
gestions that HIFs would be critical mediators of the
glycolytic state. However, while Simsek et al. showed
that LT-HSCs utilize glycolysis instead of mitochondrial
oxidative phosphorylation, coinciding with an enhanced
expression of HIF1, they did not show that HIF1 would
be strictly required to maintain the glycolytic state [8].
Takubo et al. utilized Mx1-CRE-inducible knockout
mouse models and showed that LT-HSC quiescence
depended on HIF1 expression, coupled to the capacity
Fig. 8 Inhibition of BCR-ABL does impact on the glycolytic state of K562 cells, independent of HIF signaling and hypoxia. Glucose consumption
(a) and lactate production (b) of K562 wt and ARNT knockout cells grown under normoxic and hypoxic growth conditions for 24 h cultured in
the presence of increasing doses of imatinib
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for serial transplantation, and while an increase in mito-
chondrial activity was noted, the effects on glycolysis
were not investigated [12]. In another study, making use
of the same inducible mouse model, they did study glu-
cose uptake in various stem and progenitor cell com-
partments. However, they did not see significant changes
in glucose uptake in any of these compartments in the
absence of HIF signaling, although LDH activity and lac-
tate production under hypoxia was slightly decreased
[31]. Miharada et al. showed that HIF1 controls the
number of GPR78+ HSCs, and that CRIPTO-GPR78 sig-
naling is required for HSC maintenance in the endosteal
niche and HSC quiescence, but again no direct link be-
tween HIF signaling and glycolysis was shown [13].
Studies in Hif1−/− murine embryonic fibroblasts (MEFs)
have indeed shown that cells die due to an excess of
ROS production, presumably due to a failure of making
the switch from oxidative phosphorylation to glycolysis
[53]. But glycolytic activity was not investigated in that
study, and moreover hematopoietic cells do not die
under hypoxia conditions suggesting that cell-specific
roles must exist. Taken together, while various papers
indeed indicate that HIFs can somehow control the ex-
pression of glycolytic genes in various cell types (as also
nicely reviewed in [15]), most of these do not provide
functional data in the hematopoietic stem/progenitor
cell compartment.
Possibly, the HIF-mediated control over glycolysis
genes under hypoxia acts as a safeguarding mechanism,
but is not strictly required to maintain a glycolytic state.
Obviously, many other signaling networks and transcrip-
tion factors can act on the promoters and enhancers that
drive the expression of glycolysis genes, including MYC,
STAT3/5, and the PI3K pathway, and even in the ab-
sence of HIF signaling, such pathways are apparently
sufficient to maintain glycolytic activity at high enough
levels under hypoxia. We initially hypothesized that par-
ticularly in cancer cells, which display a hyperactivation
of various pathways such as those described above would
be less dependent on HIFs to maintain a glycolytic state.
However, also in normal CB CD34+ cells we observed
that knockdown of HIF signaling did not affect the
hypoxia-induced glucose uptake and lactate production,
both under acute and chronic hypoxia conditions,
although it must be noted that these culture conditions
include relatively high cytokine concentrations that
would also induce strong activation of MYC, STAT3/5
and PI3K pathways. Indeed, when we analyzed K562 En-
code ChIP-seq datasets we observed strong binding of
STAT5 and MYC to the promoters of glycolysis genes
like SLC2A1, SLC2A3, HK1, PKM (data not shown), in-
dicating that loci are under control of various pathways.
Upon treatment of K562 cells with imatinib, we ob-
served clear reductions in glucose consumption and
lactate production both under normoxic and hypoxic
conditions, indicating that BCR-ABL can impact on the
glycolytic state of cells independently of hypoxia-
induced HIF signaling. Further studies will be needed to
determine whether real differences exist in the HIF de-
pendency of normal versus leukemic cells, but our data
clearly challenge the view that HIFs would act as onco-
genes merely by imposing a glycolytic state on cancer
cells. It is quite likely that the conditions under which
cells are studied will have a main impact on the exact
role of HIFs, and might dictate whether they act as
tumor suppressors or oncogenes, as recently extensively
discussed in various papers, but what is clear now is that
they do not simply act as gatekeepers of glycolysis.
Recently, it was shown that HIF2 is critically import-
ant for the maintenance of both normal as well as
leukemic human hematopoietic stem/progenitor cells,
whereby loss of HIF2 triggered an apoptotic response
via activation of the unfolded-protein response pathway
[20], indicating that glycolysis-independent mechanisms
might be important downstream of HIFs that control
hematopoietic stem cell fate. We find that EGR1, which
acts as a hematopoietic stem cell self-renewal factor is
also directly controlled by hypoxia, although this oc-
curred in a completely HIF-independent manner. Loss
of EGR1 results in loss of HSC quiescence and spontan-
eous mobilization [54]. EGR1 has been shown to pro-
mote hypoxia-induced autophagy [55], and we and
others recently showed that autophagy is important to
maintain HSC [56–58]. Furthermore, we observed that
specifically HIF1 but not HIF2, was able to bind and
drive BNIP3 expression, in line with data published by
Sowter et al [59]. BNIP3 interacts with processed LC3
at phagophore membranes to promote sequestration of
mitochondria within the autophagosome for degrad-
ation [59, 60]. Another HIF1-specific set of target genes
was associated with splicing, possibly in line with pub-
lished data indicating that alternative splicing may
occur under hypoxia, generally promoting exon inclu-
sion for hypoxia-induced genes, which included PDK1
[61]. Together, these data highlight the multitude of
mechanisms via which HIFs might contribute to stem
cell fate in normal and cancer cells, whereby their role
in controlling glycolysis appears to be less pronounced.
Conclusions
We have characterized the chromatin-binding profiles of
HIF1 and HIF2 in human leukemic cells in detail and
correlated that with transcriptional changes and con-
clude that these transcription factors can transactivate
all enzymes that participate in the glycolytic pathway
while OxPHOS- or glutaminolysis-related enzymes are
not controlled by HIFs. Surprisingly, however, complete
loss of HIF signaling via CRISPR/Cas9-mediated
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knockout of HIF1, HIF2, or ARNT did not at all impact
on glucose consumption or lactate production in
leukemic cells, neither in vitro nor in vivo after trans-
plantation of knockout cells to immune deficient xeno-
graft mice. Also, the hypoxia-induced glycolytic state of
healthy CD34+ cells was not affected upon knockdown
of HIF1 or HIF2. In contrast, inhibition of BCR-ABL did
impact on glucose consumption and lactate production
regardless of the presence of HIFs. These data indicate
that oncogene-mediated control over glycolysis can
occur independently of hypoxic signaling modules.
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1186/s40170-019-0206-y.
Additional file 1: Figure S1. Identification of HIF1 and HIF2 chromatin
binding sites in human leukemic cells. a. About 2/3 of HIF1-bound or
HIF2-bound loci localize close to TSSs and 1/3 do not. b. Some HIF1/2
bound loci distal form TSSs potentially regulate lncRNAs. An example
screenshot of a lncRNA potentially controlled by HIFs is shown on the
right. c. HIF binding to Chromatin modifying enzymes defined by GO RP.
d. Overlap in ChIPseq targets in K562 versus MCF7 cells. e. GO reactome
pathways in common HIF targets across different cell types.
Additional file 2: Figure S2. Identification of co-occuring transcription
factor motifs at HIF1 and HIF2-bound loci. A transcription factor (TF) motif
screen was performed to identify co-occurring TF motifs at HIF1 (a) and
HIF2 (b) loci. The overlap is shown in c. Some representative screens
shots are shown in d. NRF1, ELK1, H3K4me3, H3K27ac and H3K27me3
tracks from K562 cells were retrieved from ENCODE.
Additional file 3: Figure S3. We overexpressed HIF1 and HIF2 EGFP
fusion proteins (in K562 cells) with an empty EGFP expressing vector as
control. The cells were sorted for EGFP expression and incubated under
normoxia or hypoxia (24 hrs) as indicated. ChIP-QPCR was performed
using antibodies against EGFP (recognizing HIF:EGFP fusions), and HIF1
and HIF2 (recognizing HIF:EGFP fusions as well as endogenous HIF). b. No
HIF was present on the GATA5 locus to which HIFs do not bind.
Additional file 4: Figure S4. a. Quantitative proteome data of wt or
ARNT-/- K562 cells grown under hypoxia (24 hrs) or normoxia and protein
expression levels are shown for glycolysis, TCA and glutaminolysis-related
proteins. The K562 wt normoxia/hypoxia data are identical to those used
for Figure 3b (where fold changes are shown rather than relative protein
expression levels), but are again shown here to compare with ARNT-/-
cells. b, Rescue experiment by re-introducing the oxygen-insensitive HIF1
and HIF2 mutants in the HIF1-/- or HIF2-/- K562 cells, respectively. Q-RT-
PCRs were performed indicating that glycolysis-related genes can be re-
expressed upon overexpression of HIF mutants.
Additional file 5: Figure S5. Glucose consumption and lactate
production in CB CD34+ and K562 cells. a. Glucose consumption (left
panel) and lactate production (right panel) of K562 cells, grown for 10
days under hypoxia (1% O2). *: P<0.05, n.s.: Non-significant. b. Glucose
consumption (left panel) and lactate production (right panel) of cord-
blood. CD34+ cells after 24 hour hypoxia (1% O2), with knockdown of
ARNT. c. Knockdown efficiency of ARNT (left panel) and expression of tar-
get genes (middle and right panel) in cordblood CD34+ cells. *: P<0.05,
n.s.: Non-significant.
Additional file 6: Figure S6. 1D-NMR extract metabolite intensities from
K562 HIF1 and HIF2 knockout cells grown under hypoxia or normoxia for
24 hr. The K562 wt data is identical to that depicted in Fig. 6b but was
added here again for reference.
Additional file 7. Supplemental Methods.
Additional file 8: Supplemental Table 1. ChIPseq data.
Additional file 9: Supplemental Table 2. transcriptome data.
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